Factorial Energy Inc. targets high-value battery markets, leveraging superior performance for early aerospace and drone applications before scaling to automotive. FAC is rated ‘Buy’ based on its ...
Solid-state battery specialist Factorial Energy is teaming up with Mitsui Kinzoku, one of the few companies producing sulfide-based solid electrolytes, to scale up the promising new technology.
Factorial Funds, a venture firm launched five years ago by former Cruise engineer Sol Bier, has crossed $1 billion in realized profits, according to a letter the firm is sharing with its investors.
Factorial Energy (FAC) up 13.9% in Tuesday's trading as Oppenheimer initiated coverage with an Outperform rating and $8 price target, seeing the company as a leading play in the commercialization of ...
For years now Tim Holme has watched the same drama repeat itself roughly once a week. A headline arrives: some laboratory somewhere has cracked the problem, invented the battery of the future, solved ...
BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE)-- Factorial Energy Inc. ("Factorial") (Nasdaq: FAC), a global leader in solid-state battery technology, today announced financial and business results for the ...
Founded in the greater Boston area, Factorial develops solid-state batteries. Credit: Noah Emad / Shutterstock.com US solid-state battery developer Factorial Energy has begun trading on the Nasdaq ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is backed by ...
Electric vehicle adoption has slowed in America, but battery demand remains high, boosted by energy storage, defense, and space applications. Sellers: have no reason to accept buyers’ lower bids.
BARCELONA—Factorial closed a $150 million funding round that lifted its valuation to $2.5 billion, bringing in fresh capital to expand as artificial intelligence reshapes the business-management ...
Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results